Currently there are no established medical treatments for vestibular schwannoma. Surgery may result in vestibular nerve damage and hearing loss, while radiotherapy can lead to cranial nerve neuropathy and increase the risk of secondary malignancy. Due to its effect on the VEGF pathway, which has been shown to be dysregulated in vestibular schwannomas, bevacizumab has been investigated as a potentially efficacious medical therapy for schwannomas that are unsuitable for surgical resection. Though the place of this treatment in the paradigm of vestibular schwannoma therapy remains to be fully understood, it represents a promising advance for a complex disease for which few satisfactory options currently exist.
|Original language||English (US)|
|Title of host publication||Tumors of the Central Nervous System, Volume 7|
|Subtitle of host publication||Meningiomas and Schwannomas|
|Number of pages||5|
|State||Published - Jan 1 2012|
ASJC Scopus subject areas